BioInnovation Institute is expanding the Business Development team with Portfolio Manager Trine Bartholdy.
Trine Bartholdy has +15 years of experience in leading teams and projects within life sciences. She holds an M.Sc in Finance combined with a certificate in strategic drug development. Her first encounter with the industry was in 2000 when she as Vice President of Private Equity in Danske Bank began to invest in life science companies. Since then, she has spent four years with the Danish Growth Fund and four years with Sunstone Capital before joining the health tech NGO Maternity Foundation and later Novo Nordisk and Fertility Partnership DK.
“Trine brings important senior-level experience from venture capital, pharma, and biotech to help our start-ups accelerate. With her on board, the BII Business Development team has grown to eight people across five nationalities. A team with the passion and experience to scale BII to the world’s best incubator”, says Bobby Soni, CBO of BII.
We asked Trine a few questions about her career.
With a background in economics, why did you go into life science investments?
I highly enjoy working cross-functionally and I saw that with a background in economics I could work in any sector. I have always been interested in science and early on in my career, I worked with engineers at Rambøll, but life sciences caught my interest because it is an important tool to meet some of the many real unmet needs in the world.
When did you decide to make the turn in your career?
When I was in Danske Bank, I was approached by the Danish Growth Fund and that became a turning point for me. I was on a good path to a financial career, but I had to decide whether I wanted to pursue that or leave to do what I found to be more compelling. I went with life sciences because working with something that brings real positive change to people’s lives has always been a driver for me.
Why did you say yes to joining BII?
The first time, I heard about BII was three years ago. I had been working in both venture capital and the pharmaceutical industry, so I knew there was a need for a good framework in the Nordics to facilitate company creation. It planted a seed in me back then to learn about the ambitious set-up at BII and when the opportunity to join the compelling journey arose, I said yes.
What do you look forward to?
I look forward to driving new and promising science. And I’m very excited to be working with an engaged and experienced business development team in what I believe to be one of the leading frameworks available for life science start-ups in Europe. BII has a broad scope within therapeutics that can improve lives, health tech that can improve health outcomes as well as making it more accessible and bio-industrial that can help us in climate change. All of which are truly important needs.